CL2014000775A1 - Compuestos derivados de estra-1,3,5(10),16-tetraen-3-carboxamida; inhibidores de akr1c3; medicamentos que los contienen; y su uso para el tratamiento y/o la prevencion de endometriosis, dismenorrea, acne, alopecia, madurez sexual precoz, cancer de mama, cancer de pulmon, epoc, obesidad y dolor inflamatorio, entre otras. - Google Patents

Compuestos derivados de estra-1,3,5(10),16-tetraen-3-carboxamida; inhibidores de akr1c3; medicamentos que los contienen; y su uso para el tratamiento y/o la prevencion de endometriosis, dismenorrea, acne, alopecia, madurez sexual precoz, cancer de mama, cancer de pulmon, epoc, obesidad y dolor inflamatorio, entre otras.

Info

Publication number: CL2014000775A1
Authority: CL; Chile
Prior art keywords: epoc; tetraen; estra; dysmenorrhea; endometriosis
Prior art date: 2011-09-29

Application number

CL2014000775A

Other languages

English (en)

Inventor

Ulrich Bothe

Naomi Barak

Matthias Busemann

Oliver Martin Fischer

Andrea Rotgeri

Isabella Gashaw

Ingo Hartung

Tobias Marquardt

Original Assignee

Bayer Pharma AG

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-29

Filing date

2014-03-28

Publication date

2014-08-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000775(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-28 Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG

2014-08-18 Publication of CL2014000775A1 publication Critical patent/CL2014000775A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Pregnancy & Childbirth (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2014000775A 2011-09-29 2014-03-28 Compuestos derivados de estra-1,3,5(10),16-tetraen-3-carboxamida; inhibidores de akr1c3; medicamentos que los contienen; y su uso para el tratamiento y/o la prevencion de endometriosis, dismenorrea, acne, alopecia, madurez sexual precoz, cancer de mama, cancer de pulmon, epoc, obesidad y dolor inflamatorio, entre otras. CL2014000775A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102011083725A DE102011083725A1 (de)	2011-09-29	2011-09-29	Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Publications (1)

Publication Number	Publication Date
CL2014000775A1 true CL2014000775A1 (es)	2014-08-18

Family

ID=46963705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000775A CL2014000775A1 (es)	2011-09-29	2014-03-28	Compuestos derivados de estra-1,3,5(10),16-tetraen-3-carboxamida; inhibidores de akr1c3; medicamentos que los contienen; y su uso para el tratamiento y/o la prevencion de endometriosis, dismenorrea, acne, alopecia, madurez sexual precoz, cancer de mama, cancer de pulmon, epoc, obesidad y dolor inflamatorio, entre otras.

Country Status (42)

Country	Link
US (1)	US9487554B2 (es)
EP (1)	EP2760878B1 (es)
JP (1)	JP5791810B2 (es)
KR (1)	KR20140069013A (es)
CN (1)	CN103827133B (es)
AP (1)	AP2014007598A0 (es)
AR (1)	AR088180A1 (es)
AU (1)	AU2012314627B2 (es)
BR (1)	BR112014007223A2 (es)
CA (1)	CA2850047C (es)
CL (1)	CL2014000775A1 (es)
CO (1)	CO6920294A2 (es)
CR (1)	CR20140144A (es)
CU (1)	CU20140037A7 (es)
CY (1)	CY1117123T1 (es)
DE (1)	DE102011083725A1 (es)
DK (1)	DK2760878T3 (es)
DO (1)	DOP2014000059A (es)
EA (1)	EA025518B9 (es)
EC (1)	ECSP14013275A (es)
ES (1)	ES2560257T3 (es)
GT (1)	GT201400059A (es)
HR (1)	HRP20160050T1 (es)
HU (1)	HUE026645T2 (es)
IL (1)	IL231755A (es)
JO (1)	JO3122B1 (es)
MA (1)	MA35455B1 (es)
MX (1)	MX2014003823A (es)
MY (1)	MY175804A (es)
PE (1)	PE20141554A1 (es)
PH (1)	PH12014500674A1 (es)
PL (1)	PL2760878T3 (es)
PT (1)	PT2760878E (es)
RS (1)	RS54521B1 (es)
SG (1)	SG11201400144SA (es)
SI (1)	SI2760878T1 (es)
TN (1)	TN2014000131A1 (es)
TW (1)	TWI537284B (es)
UA (1)	UA107550C2 (es)
UY (1)	UY34356A (es)
WO (1)	WO2013045407A1 (es)
ZA (1)	ZA201401568B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6196302B2 (ja)	2012-07-10	2017-09-13	バイエル・ファルマ・アクティエンゲゼルシャフト	３−置換エストラ−１，３，５（１０），１６−テトラエン誘導体、その調製法、これらを含む医薬製剤および医薬を調製するためのその使用
SG11201505875WA (en) *	2013-02-21	2015-09-29	Bayer Pharma AG	Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (akr1 c3)
US20170260226A1 (en) *	2014-09-11	2017-09-14	Bayer Pharma Aktiengesellschaft	3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
US10167293B2 (en)	2016-05-26	2019-01-01	Bayer Pharma Aktiengesellschaft	[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs)	2016-06-07	2018-08-22	Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i.	15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (en)	2016-07-11	2018-01-17	Bayer Pharma Aktiengesellschaft	Low-dosed oral dosage form of an akr1c3 inhibitor for treatment of diseases
CA3047196A1 (en)	2016-12-19	2018-06-28	Bayer Pharma Aktiengesellschaft	[(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
US20200087284A1 (en)	2016-12-19	2020-03-19	Bayer Pharma Aktiengesellschaft	[4-(phenylsulfonyl)piperazin-1-yl](1h-1, 2, 3-triazol-4-yl)methanones
TW201825478A (zh)	2016-12-19	2018-07-16	德商拜耳製藥公司	［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3421483A1 (en)	2017-06-29	2019-01-02	Bayer Pharma Aktiengesellschaft	Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
CN108503695B (zh) *	2018-03-09	2021-06-08	南方医科大学南方医院	基于GnRH多肽衍生物的示踪剂及其制备方法和应用
CN110693892A (zh) *	2018-07-09	2020-01-17	深圳艾欣达伟医药科技有限公司	化合物用于制备预防、治疗或改善疼痛的药物的用途
JP7644713B2 (ja)	2019-03-06	2025-03-12	プロペラセラピューティクスインコーポレイテッド	アビラテロンプロドラッグ
CN113683648B (zh) *	2021-08-26	2025-03-07	上海皓鸿生物医药科技有限公司	一种2’-氟-2’-脱氧尿苷的合成方法及其中间体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4632003A (en)	1985-07-15	1986-12-30	Kopp William L	Musical instrument sound quality enhancement device
DK0633893T3 (da) *	1992-03-31	2000-04-17	Btg Int Ltd	17-Substituerede steroider, der er nyttige ved cancerbehandling
US5604213A (en)	1992-03-31	1997-02-18	British Technology Group Limited	17-substituted steroids useful in cancer treatment
BR9908592A (pt)	1998-03-11	2001-04-24	Endorech Inc	Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
EP1756139A4 (en) *	2004-03-12	2009-07-29	Entremed Inc	ANTI-ANGIOGENIC AGENTS
MX2009005201A (es) *	2006-11-30	2009-05-27	Solvay Pharm Gmbh	Derivados de estratrieno sustituidos como inhibidores de 17beta hsd.
GB2470700B (en)	2008-03-25	2012-08-08	Univ Maryland	C-17 heteroaryl steroidal CYP17 inhibitors
CA2761389A1 (en)	2009-02-05	2010-08-12	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR101855453B1 (ko)	2010-04-27	2018-06-20	파르마 마르 에스.에이.	7(8) 위치가 불포화된 항암 스테로이드계 락톤

2011
- 2011-09-29 DE DE102011083725A patent/DE102011083725A1/de not_active Withdrawn
2012
- 2012-09-24 JP JP2014532337A patent/JP5791810B2/ja not_active Expired - Fee Related
- 2012-09-24 MY MYPI2014700715A patent/MY175804A/en unknown
- 2012-09-24 WO PCT/EP2012/068803 patent/WO2013045407A1/de not_active Ceased
- 2012-09-24 CN CN201280047810.1A patent/CN103827133B/zh not_active Expired - Fee Related
- 2012-09-24 ES ES12766636.0T patent/ES2560257T3/es active Active
- 2012-09-24 EA EA201490653A patent/EA025518B9/ru not_active IP Right Cessation
- 2012-09-24 PE PE2014000441A patent/PE20141554A1/es active IP Right Grant
- 2012-09-24 MX MX2014003823A patent/MX2014003823A/es unknown
- 2012-09-24 AU AU2012314627A patent/AU2012314627B2/en not_active Ceased
- 2012-09-24 DK DK12766636.0T patent/DK2760878T3/en active
- 2012-09-24 RS RS20160023A patent/RS54521B1/sr unknown
- 2012-09-24 KR KR1020147007566A patent/KR20140069013A/ko not_active Abandoned
- 2012-09-24 AP AP2014007598A patent/AP2014007598A0/xx unknown
- 2012-09-24 PT PT127666360T patent/PT2760878E/pt unknown
- 2012-09-24 CA CA2850047A patent/CA2850047C/en not_active Expired - Fee Related
- 2012-09-24 SG SG11201400144SA patent/SG11201400144SA/en unknown
- 2012-09-24 US US14/348,645 patent/US9487554B2/en not_active Expired - Fee Related
- 2012-09-24 HU HUE12766636A patent/HUE026645T2/en unknown
- 2012-09-24 SI SI201230440T patent/SI2760878T1/sl unknown
- 2012-09-24 UA UAA201404419A patent/UA107550C2/uk unknown
- 2012-09-24 PH PH1/2014/500674A patent/PH12014500674A1/en unknown
- 2012-09-24 BR BR112014007223A patent/BR112014007223A2/pt not_active Application Discontinuation
- 2012-09-24 HR HRP20160050TT patent/HRP20160050T1/hr unknown
- 2012-09-24 PL PL12766636T patent/PL2760878T3/pl unknown
- 2012-09-24 EP EP12766636.0A patent/EP2760878B1/de active Active
- 2012-09-27 JO JOP/2012/0285A patent/JO3122B1/ar active
- 2012-09-28 TW TW101136042A patent/TWI537284B/zh not_active IP Right Cessation
- 2012-09-28 UY UY0001034356A patent/UY34356A/es not_active Application Discontinuation
- 2012-09-28 AR ARP120103610A patent/AR088180A1/es unknown
2014
- 2014-02-28 ZA ZA2014/01568A patent/ZA201401568B/en unknown
- 2014-03-27 MA MA36857A patent/MA35455B1/fr unknown
- 2014-03-27 IL IL231755A patent/IL231755A/en active IP Right Grant
- 2014-03-28 DO DO2014000059A patent/DOP2014000059A/es unknown
- 2014-03-28 TN TNP2014000131A patent/TN2014000131A1/en unknown
- 2014-03-28 CR CR20140144A patent/CR20140144A/es unknown
- 2014-03-28 CL CL2014000775A patent/CL2014000775A1/es unknown
- 2014-03-28 EC ECSP14013275 patent/ECSP14013275A/es unknown
- 2014-03-28 GT GT201400059A patent/GT201400059A/es unknown
- 2014-03-28 CU CU2014000037A patent/CU20140037A7/es unknown
- 2014-03-28 CO CO14066898A patent/CO6920294A2/es unknown
2016
- 2016-01-18 CY CY20161100045T patent/CY1117123T1/el unknown

Also Published As

Publication number	Publication date
PT2760878E (pt)	2016-02-26
US20140249119A1 (en)	2014-09-04
MY175804A (en)	2020-07-09
CN103827133B (zh)	2015-11-25
MX2014003823A (es)	2014-06-04
PE20141554A1 (es)	2014-10-24
CN103827133A (zh)	2014-05-28
UA107550C2 (uk)	2015-01-12
ZA201401568B (en)	2016-11-30
GT201400059A (es)	2015-02-17
ECSP14013275A (es)	2014-04-30
PL2760878T3 (pl)	2016-04-29
AP2014007598A0 (en)	2014-04-30
IL231755A (en)	2016-06-30
MA35455B1 (fr)	2014-09-01
US9487554B2 (en)	2016-11-08
CA2850047A1 (en)	2013-04-04
AU2012314627B2 (en)	2016-08-18
EA201490653A1 (ru)	2014-09-30
DE102011083725A1 (de)	2013-04-04
TW201317253A (zh)	2013-05-01
EP2760878B1 (de)	2015-10-28
EA025518B9 (ru)	2017-10-31
HK1197414A1 (zh)	2015-01-16
CR20140144A (es)	2014-05-16
HRP20160050T1 (hr)	2016-02-12
KR20140069013A (ko)	2014-06-09
BR112014007223A2 (pt)	2017-04-04
TN2014000131A1 (en)	2015-07-01
AR088180A1 (es)	2014-05-14
DOP2014000059A (es)	2014-06-15
TWI537284B (zh)	2016-06-11
JP2014527994A (ja)	2014-10-23
NZ622081A (en)	2015-10-30
EP2760878A1 (de)	2014-08-06
CY1117123T1 (el)	2017-04-05
CO6920294A2 (es)	2014-04-10
UY34356A (es)	2013-04-30
JO3122B1 (ar)	2017-09-20
CU20140037A7 (es)	2014-07-30
PH12014500674A1 (en)	2021-08-09
HUE026645T2 (en)	2016-07-28
CA2850047C (en)	2016-03-29
WO2013045407A1 (de)	2013-04-04
SI2760878T1 (sl)	2016-02-29
DK2760878T3 (en)	2016-01-25
ES2560257T3 (es)	2016-02-18
AU2012314627A1 (en)	2014-04-10
SG11201400144SA (en)	2014-05-29
RS54521B1 (sr)	2016-06-30
JP5791810B2 (ja)	2015-10-07
EA025518B1 (ru)	2016-12-30

Publication	Publication Date	Title
CL2014000775A1 (es)	2014-08-18	Compuestos derivados de estra-1,3,5(10),16-tetraen-3-carboxamida; inhibidores de akr1c3; medicamentos que los contienen; y su uso para el tratamiento y/o la prevencion de endometriosis, dismenorrea, acne, alopecia, madurez sexual precoz, cancer de mama, cancer de pulmon, epoc, obesidad y dolor inflamatorio, entre otras.
CY1124407T1 (el)	2022-07-22	Ενωσεις αναστολεα αυτοταξινης
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CR20120202A (es)	2012-06-12	Métodos y composiciones para tratar cáncer
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
IL235261B (en)	2021-02-28	Antibodies against claudin 18.2 useful in cancer diagnosis
IL248797B (en)	2021-05-31	Anti-human papillomavirus 16 e7 t cell receptors
CY1118187T1 (el)	2017-06-28	Χημικες ενωσεις
BR112016008541A2 (pt)	2017-09-12	composições úteis para tratar distúrbios relacionados a kit
BR112015011756A2 (pt)	2017-07-11	inibidores da glutamase e métodos de uso
BR112015011112A2 (pt)	2018-11-06	composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
BR112015001838A2 (pt)	2017-07-04	composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
EP2971034A4 (en)	2016-11-30	COMPOSITIONS, METHODS AND DEVICES FOR SYNTHESIS OF OLIGONUCLEOTIDES
IL239981B1 (en)	2023-05-01	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL235607A0 (en)	2015-01-29	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HRP20220897T8 (hr)	2022-11-11	Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
MX2015004771A (es)	2016-01-08	Metodos para tratar cancer.
CL2013002939A1 (es)	2014-07-04	Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
SMP200900085B (it)	2010-11-12	3-imidazolil-indoli per il trattamento di malattieproliferative.
WO2015023976A3 (en)	2015-04-23	Selective grp94 inhibitors and uses thereof
ATE538652T1 (de)	2012-01-15	Synergistische pharmazeutische kombination für die behandlung von krebs
BRPI0911112A2 (pt)	2015-10-06	composições e métodos para o tratamento do câncer de mama
CL2015002346A1 (es)	2015-12-28	Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CL2016003074A1 (es)	2017-04-28	Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
ZA201706402B (en)	2019-01-30	C.novyi for the treatment of solid tumors in humans